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ABSTRACT
Objective: To determine the degree of correlation between the WHO clinical staging 
and CD4 T-cell counts in HIV/AIDS adults at Kenyatta National Hospital, Nairobi.
Design: Cross-sectional study.
Setting: Kenyatta National Hospital, Nairobi. 
Subjects:  One hundread and fifty two newly diagnosed HIV patients were recruited 
prospectively. Patients were first staged using the 2005 WHO clinical staging and then 
blood drawn for CD4 cell count. 
Results: The mean age in the study was 35 years, with females comprising 52.6% of the 
study group. The mean CD4 counts were 455, 420, 203 and 92 for WHO Stage 1, 2, 3 and 
4 respectively. The sensitivity of the WHO clinical staging to predict CD4 counts of 
>350cells/μl was 63% with a specificity of 82%. The most common HIV clinical events 
were bacterial infections (33%), severe weight loss(28%) and tuberculosis(27%).
Conclusions: There was correlation between the WHO clinical staging and expected 
CD4 T-cell count. However, the sensitivity was low and missed over a third of the 
patients in need of HAART. Majority of the patients presented in severe disease in 
need of HAART at the onset of their HIV diagnosis with 107 (70.3%) of the patients 
with Stage 3 or 4 disease and 114 (75%) of patients with CD4 counts of <350 cells/μl. 
INTRODUCTION
The Human Immunodeficiency Virus (HIV) infects 
and destroys CD4+ T lymphocyte cells, leading to 
their persistent decline in number and function as 
the disease progresses (1-7).
 Since the first cases of HIV were described (8-10), 
various clinical staging systems have been developed 
after observations that different opportunistic 
infections occurred at specific CD4 T-cell counts. 
The most widely used are the Centre for Disease 
Control (CDC) classification and the World Health 
Organization (WHO) clinical staging.
 The WHO clinical staging was first developed 
in 1990  (11), and emphasised the use of clinical 
parameters to guide clinical decision-making for the 
management of HIV/AIDS patients. It was designed 
for use in resource limited settings where there was 
limited access to laboratory services and can be used 
to guide HIV care even in the absence of CD4 T-cell 
count. This is unlike the CDC classification which 
requires both the clinical stage and CD4 count for 
classification. The WHO staging has been revised 
severally with the current one produced in 2005 
(12).
 The WHO clinical staging is a tool that was 
designed to identify HIV/AIDS related clinical events 
using clinical presentation and simple laboratory and 
radiological investigations, with the clinical diagnosis 
being either presumptive or definitive depending on 
the tiers of investigation carried out. This has enabled 
WHO as well as countries in Africa, particularly 
Sub-Saharan Africa, which has borne the brunt of 
the HIV/AIDS pandemic, to provide HIV care and 
treatment with limited resources. 
 Being a symptom based tool, the WHO clinical 
staging may not correctly identify the opportunistic 
infections. Similarly, patients may have no clinical 
symptoms despite low CD4 T-cell counts. Thus, if 
used alone, the WHO clinical stage may disqualify 
patients for initiation of HAART despite advanced 
immunologic disease.  
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 CD4 T-cell count is the single most useful 
parameter for evaluation of HIV disease as well as 
for prognostication. Where available, it forms the 
cornerstone of HIV/AIDS care as manifestation of 
opportunistic infections correlate with the level of 
CD4 counts. However, it is expensive and is not 
readily available.    
 This study was undertaken to establish the degree 
of correlation between the WHO clinical staging 
and CD4 T-cell counts in newly diagnosed patients 
presenting to the Kenyatta National Hospital.
MATERIALS AND METHODS
A prospective study was carried out by recruiting 
newly diagnosed HIV positive patients aged between 
18 and 49 years presenting either to the inpatient 
medical wards or the outpatient HIV clinic. A total 
of 152 patients were recruited, 76 from the outpatient 
clinic, 76 from the medical wards. The mean duration 
of diagnosis was nine days and had not been on 
cotrimoxazole prophylaxis prior to recruitment into 
the study. Patients who were on steroids, cytotoxic 
drugs or with a non-HIV malignancy were excluded 
from the study. Patients were evaluated and staged 
using the Interim WHO 2005 clinical staging of HIV/
AIDS and HIV/AIDS case definitions for surveillance 
(African region) (12). Laboratory and radiological 
methods were carried out if they were required to 
make a clinical diagnosis. In the majority of the cases, 
the HIV clinical events were presumptive diagnosis 
and based on the WHO clinical staging for adults and 
adolescents: presumptive and definitive criteria for 
recognising HIV/AIDS related clinical events (12).   
 Blood for CD4 T-cell count was drawn after the 
clinical staging had been done. Level of CD4 count 
was determined using Partec Cytoflow method, with 
the results made  available after one to four days.  
 Analysis of the Data was done using SPSS 17.0. 
Student t-test was used for continuous variables 
and chi-square for proportions.  Correlation was 
done using spearman’s rank correlation coefficient. 
Two by two tables were used to calculate sensitivity, 
specificity, positive predictive value and negative 
predictive value.
RESULTS  
The study was carried out between April 2010 and 
February 2011 both in the outpatient HIV clinic as well 
as inpatient medical wards. The patient characteristics 
were tabulated as shown.                                               
Table 1
Socio-demographic profile ( N=152)
Socio-demographi characteristics All patients (N=152) No (%)
Age –years ±2SD 35.25 ±1.71
Female sex 80(52.6)
Marital status-married 100 (65.1)
Education primary and below 71 (46.7)
Education secondary and above 81 (53.3)
Occupation employed 87 (57.2%) 
Mode of hiv diagnosis (VCT) 70 (46.1)
Mode of hiv diagnosis (PITC) 82(53.9%)
The mean age of the study group was 35.25 years with a female predominance of 52.6%.
65% of the patients were married with 53.3% having attained at least high school education.
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Table 2
Prevalence of HIV/AIDS related clinical events (N=152)
HIV/AIDS related clinical events Number of patients (%)
Asymptomatic/ PGL 26 (17.1%)
Papular pruritic eruptions 22 (14.5%)
Moderate weight loss <10% 13 (8.6%)
Herpes zoster 10 (6.6%)
Fungal nail infections of the fingers 3 (2.0%)
Angular chelitis 2 (1.3%)
Seborrhoeic dermatitis 1 (0.7%)
Severe weight loss >10% 43 (28.3%)
Bacterial infections  51 (33.6%)
Bacterial infection (Pneumonia) 28 (18.4%)
Bacterial infection (Meningitis) 10 (6.6%)
Bacterial infection(e.g septicaemia,pyomyositis,UTI) 13 (8.6%)
Pulmonary Tuberculosis 18 (11.8%)
Oral thrush 18 (11.8%)
Chronic gastroenteritis  3 (2.0%)
Oral hairy leukoplakia 2 (1.3%)
Extrapulmonary Tuberculosis 23 (15.1%)
Cryptococcal meningitis 8 (5.3%)
HIV wasting syndrome 4 (2.6%)
Esophageal candidiasis 4 (2.6%)
Chronic herpes simplex infection 3 (2.0%)
HIV encephalopathy  3 (2.6%)
Pneumocystis jiroveci pneumonia 2 (1.3%)
Kaposi’s sarcoma 2 (1.3%)
Cerebral toxoplasmosis 2 (1.3%)
Invasive cancer of the cervix 1 (0.7%)
CMV retinitis 1 (0.7%)
Majority of the patients presented with one or more HIV clinical events. The most prevalent HIV/
AIDS related clinical events were bacterial infections (34%), severe weight loss (28%) and Tuberculosis 
(27%). 
Table 3
Comparison of clinical staging and CD4 count difference (N=152)
WHO clinical stage Mean Median 95% CI WHO CD4 count range
Stage 1 (26) 455 388 334- 575 >500
Stage 2 (19) 420  347 302- 538 350- 499
Stage 3 (59) 203                140 153- 252 200- 349
Stage 4 (48) 92 44 58- 127 <200
All stages (152) 238 158 198- 278 -
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There was correlation between the mean CD4 T- 
cell counts in comparison to the WHO guidelines 
recommendations in Stages 2, 3 and 4 with the 
mean and 95% confidence interval being within the 
expected values.
 The mean CD4 count in Stage 1 was lower than 
expected from the WHO guidelines.  
 Spearman’s correlation coefficient between the 
WHO clinical staging and CD4 count was -0.583 (p 
< 0.01).
Table 4
Sensitivity and specificity of clinical staging to predict 
CD4 counts of 200
 
 CD4 >200 CD4< 200
WHO stage 1&2        36 9
WHO stage 3&4 31 76
The sensitivity of the WHO clinical staging to predict 
CD4 T-cell counts of 200 cells/μl  was 53% with 
specificity of 89%. The positive predictive value was 
80% and the negative predictive value= 71%
Table 5
Sensitivity and specificity of clinical staging to predict 
CD4 counts of 350
 CD4 >350 CD4< 350
WHO stage 1&2 24 21
WHO stage 3&4 14 93
The sensitivity of the WHO clinical staging to predict 
CD4 T-cell counts of 350 cell/μl was 63% with 
specificity of 82%. The positive predictive value was 
53% and the negative predictive value was 87%.
DISCUSSION
The WHO clinical staging was a tool developed 
to be used in resource constrained settings where 
facilities for CD4 count may not be readily available. 
The Original WHO clinical staging was published in 
1990 (11)  after observations that certain opportunistic 
infections occurred at specific CD4 T-cell counts. Our 
study was carried out using the interim WHO 2005 
clinical staging of HIV/AIDS and HIV/AIDS case 
definitions for surveillance (African region) (12). 
 In this study, 152 newly diagnosed HIV patients 
diagnosed either by rapid test or Elisa method were 
recruited. Diagnosis was either through the outpatient 
voluntary counselling and testing (VCT) or through 
provider initiated testing and counselling (PITC). 
The mean duration of HIV diagnosis at recruitment 
was nine days. Patients recruited into the study were 
HAART-naive and had never used cotrimoxazole 
prophylaxis. 
 The overall sex distribution was 52.6% female 
and 47.4% male. Outpatient arm comprised of 53.9% 
female and 46.1% male. Inpatient arm was 51.3% 
female and 48.7% male. Studies carried out in the 
comprehensive care centre (CCC) have shown a 
higher female preponderance (13-15).
 The Kenya 2009 Population and Housing Census 
showed that an almost equal male to female ratio 
countrywide as well as in Nairobi province (16). HIV 
prevalence studies done in Kenya have shown both 
higher rates of HIV as well as higher HIV testing 
amongst females (17-19).  
 Sixty five point eight percent of the patients 
were married. This concurs with other studies that 
have shown almost half of new HIV infections occur 
among married couples (18,20). 
 The most common HIV/AIDS related clinical 
events in this study was bacterial infection which 
occurred in 51 patients (34%). Tuberculosis (both 
pulmonary and extrapulmonary) was the third most 
common and was diagnosed in 41 patients (27%). 
Cryptococcal meningitis was diagnosed in eight of our 
patients (5%). Most of these were presumptive clinical 
diagnosis as histopathologic diagnosis was lacking. 
The high incidence in TB in the study population is 
in keeping with the national estimates. According to 
National/AIDS/STD Control Program (NASCOP) 
and the National Tuberculosis and Leprosy Program, 
TB is the most common opportunistic infection in 
persons living with HIV/AIDS and accounts for a 
third of all AIDS related deaths.  
 In patients who had chest radiographs done as 
part of the workup for the illness, 22 had a radiologic 
diagnosis of TB (55%) while three patients had 
features of pneumonia (7.5%). Thirteen patients had 
chest radiographs reported as normal despite having 
symptoms of respiratory disease. Two patients had 
no radiological evidence of pulmonary TB despite 
having sputum positive for AAFBs. 
 In this study population, 70.4% of the patients 
presented in stage 3 or 4 with only 29.6% of the 
patients having clinical stage 1 or 2 disease at the time 
of diagnosis of their HIV disease. Most of the patients 
in our series presented with severe symptomatic 
disease despite the availability of free VCT services 
countrywide. According to the National AIDS/STD 
Control Program (NASCOP), there are 156 registered 
VCTs in Nairobi and 952 countrywide (21). The KAIS 
2007 (18) report showed that 83% of HIV-infected 
people were unaware of their status. This may be an 
indication that the majority of HIV infected persons 
are diagnosed with HIV either through VCT or 
PITC services only after they have symptomatic and 
advance disease.
 Similarly, 75% of the patients in this series 
presented with CD4 T-cell counts of <350 cells/μl. 
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Overall, more than 70% of our patients qualified for 
HAART at the very onset based on their CD4 cell 
count or clinical stage and were in urgent need for 
commencement of HAART.
 Our study found an overall mean CD4 T-cell 
count of 455 for Stage 1, 420 for Stage 2, 203 for Stage 
3 and 92 for Stage 4. The mean CD4 T cell counts in all 
the 4 clinical stages were less than 500 cells/μl.  These 
results are comparable to other studies carried out 
by Edathoju et al in Saudi Arabia (22) and Kassa et al 
in Addis Ababa (23) which demonstrated correlation 
with CD4 T-cell counts. These findings support the 
use of WHO clinical staging as a surrogate marker 
for the level of immunosuppression in leau of CD4 
T-cell counts. 
 Using the previous WHO cutoff for initiation of 
HAART of 200 cells/μl, our study had a sensitivity 
of 53% and specificity of 89%. Similar results were 
reported in other studies (24-27).  Kaagayi et al (25) 
found a sensitivity 51% and specificity of 88% with 
CD4 cutoffs of 200 cells/μl. In a study by Jaffar et al 
(25) sensitivity was 52% and specificity 68% of the 
clinical staging to predict CD4 counts of 200cells/
μl. In a study carried out in Thailand by Costello 
et al (26) the WHO clinical staging criteria had a 
sensitivity of 33% in identifying patients with CD4 
counts of 200cells/μl. A similar study carried out in 
Tanzania by Morpeth et al (27) had a higher sensitivity 
of 75% but a low specificity of 36%. These studies 
demonstrate very low sensitivity and miss nearly 
half of the patients in need of HAART if the previous 
cutoff of 200 cells/μl is used.
 In this study, the WHO clinical stage had a 
sensitivity of 63% in correctly predicting CD4 counts 
greater than 350 cells/μl and specificity of 82% in 
identifying patients with CD4 counts less than 350 
cells/μl. A similar study carried out at Makerere 
University in Kampala by Baveewo et al (28) found 
that in WHO Clinical Stage 1 and 2, the sensitivity 
to predict CD4 T-cell counts of 350 cells/μl was 
only 49.1%. These studies underscore the need for 
CD4 testing in these patients in order to correctly 
identify patients in need of HAART despite being 
in clinical stage 1 and 2. The high specificity in our 
study demonstrates that patients presenting with 
severe symptomatic disease are likely to have a low 
CD4 count. This demonstrates that if the clinical 
staging was used to identify stage 3 and 4 patients 
in need of HAART, majority (87%) of the patients 
would be correctly identified. However, the current 
WHO guidelines recommend HAART initiation in 
clinical stage 3 and 4 irrespective of CD4 counts and 
as such ,these patients  with CD4 counts greater than 
350 cells/μl qualify for initiation of HAART.
 In this study 21 (14%) of the patients with clinical 
stage 1 and 2 had CD4 counts below 200 cells/μl; of 
these, 12 (8%) had CD4 counts between 200 and 350 
cells/μl , while 9 (6%) had CD4 counts below 200 cells/
μl. Thus if treatment was delayed on the basis of the 
WHO clinical staging alone, the risk of developing 
severe opportunistic infections or dying was twice 
as likely in the 9 patients with CD4 counts less than 
200 cells/μl as compared to the 12 patients with CD4 
counts between 200 and 350 cells/μl. Wilkin et al (29) 
demonstrated that the optimal time for initiation of 
HAART was when CD4 T-cell counts fell to below 
350 cells/μl in order to prevent both HIV-related as 
well as non-HIV-related clinical events. A similar 
study carried out by Kaplan et al (30) showed that the 
risk of opportunistic infections or death was twice as 
high in patients initiated on HAART at CD4 counts 
of 50-199 cells/μl (Hazard ratio 3.5) as compared to 
CD 4 counts of 200- 350 cells/μl ( Hazard ratio 1.7) 
in comparison to patients with CD4 counts of greater 
than 500 cells/μl.  
 By increasing the cutoff for HAART from 200 
cells/μl to 350 cells/μl, the sensitivity of the study 
increased from 53% to 63% with a slight decline of 
specificity from 89% to 82%. Thus, the WHO clinical 
staging has became a more relevant tool in identifying 
patients in need of HAART with the use of the 
current guidelines of 350 cells/μl as compared to the 
previous guidelines of 200 cells/μl. This will enable 
more patients to be correctly identified for initiation 
of HAART if CD4 counts are lacking. 
 This study demonstrated that in HIV/AIDS 
patients presenting to KNH, there was correlation 
between the WHO clinical stage and expected CD4 
T-cell count. Moreover, the WHO clinical staging had 
a high specificity and was able to correctly identify 
82% of patients with CD4 counts of less than 350cells/
μl. However, the sensitivity was low and missed 37% 
of patients with CD4 T-cell count of less than 350 
cells/μl. These results are comparable to studies done 
elsewhere which demonstrate the low sensitivity of 
the WHO clinical staging (25-28).
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